BODY PHARM Archives

MOTS-C mainly affects how the body handles metabolism, controlling glucose levels, improving insulin sensitivity, and helping the body manage stress. It encourages cells to take in more glucose by activating AMPK, which means energy is used efficiently during times of metabolic demand, like fasting or exercise.

By blocking the folate cycle, MOTS-C directs resources towards glycolysis, allowing energy to be produced even when mitochondria aren’t working optimally. It also makes the body more responsive to insulin, showing promise for treating type 2 diabetes and metabolic syndrome.

As a peptide that responds to stress, it boosts mitochondrial function and helps create new mitochondria. Furthermore, it supports healthy aging by reducing inflammation and slowing mitochondrial damage. This offers exciting possibilities for treating metabolic and age-related diseases.

MOTS-C helps regulate energy balance and supports healthy metabolism. Research shows it activates AMPK pathways, improves insulin sensitivity and enhances exercise performance. It may also reduce fat gain and support mitochondrial function. Studies link MOTS-C with better muscle strength, endurance, and metabolic flexibility, suggesting it plays an important role in maintaining energy and overall metabolic health.

MOTS-C may begin affecting metabolism and energy use within days in experimental studies. Research in animals shows improved insulin sensitivity and endurance after short-term use, often within one to two weeks. These effects relate to its role in activating AMPK pathways, which help regulate energy balance and support better physical performance over time.

MOTS-C helps the body manage energy and blood sugar more effectively. Studies show it activates AMPK pathways that improve insulin sensitivity and glucose use. It may also protect against insulin resistance linked to diet or aging. Research suggests MOTS-C supports healthy metabolism and may help control blood sugar levels, making it a promising focus for diabetes-related studies.

BP TESAMORELIN 32 PEN

R 2900

The Body Pharm Tesamorelin 32 Pen is a premium peptide therapy designed to support fat loss, specifically targeting stubborn visceral fat, while enhancing natural growth hormone production and metabolic health.

Tesamorelin is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). It stimulates the pituitary gland to increase the body’s natural production of growth hormone, which in turn elevates IGF-1 levels.

Unlike direct fat burners, Tesamorelin works by optimising your body’s own hormone pathways.

The Body Pharm Tesamorelin 32 Pen offers a targeted, clinically backed approach to reducing visceral fat while supporting natural hormone optimisation, making it a powerful addition to any fat-loss or body recomposition protocol.

BP NAD + 1000 PEN

R 2400

Elevate your wellness journey with NAD+ 1000mg a premium subcutaneous injection supplement formulated to restore and optimise Nicotinamide Adenine Dinucleotide (NAD+) levels in your body. Essential for cellular energy production, DNA repair, and overall cellular health, NAD+ is a cornerstone of vitality and longevity.

Each kit contains a 1000mg vial of NAD+, carefully measured for subcutaneous injection. Designed with flexibility in mind, the dosage can be tailored to individual health goals. Begin with smaller doses and adjust as needed, with professional guidance. Detailed instructions are included for confident at home administration.

Boost your energy, sharpen your cognitive focus, and support metabolic health with NAD+ supplementation. By aiding in cellular repair and reducing oxidative stress, NAD+ promotes anti-ageing benefits and contributes to overall vitality.

The at-home injection is designed for ease and simplicity, empowering you to incorporate NAD+ into your routine without the need for clinic visits. Proper training or consultation with a healthcare provider is recommended to ensure safe and effective use.

Proper storage of NAD+ is key to maintaining its potency. This product includes storage instructions—typically involving refrigeration and protection from light—to ensure optimal efficacy.

Nicotinamide Adenine Dinucleotide (NAD) is a coenzyme found in all living cells, playing a critical role in fundamental biological processes:

Energy production: NAD is vital for converting nutrients into cellular energy, ensuring your body operates at peak efficiency.

DNA Repair: It supports cellular mechanisms that repair DNA, helping to maintain genetic integrity over time.

Cellular Health: By reducing oxidative stress and promoting cell function, NAD helps fight the effects of ageing and supports overall well-being.

Overtime, NAD levels decline due to ageing and lifestyle factors, which can impact energy, cognition, and metabolic health. Supplementing with NAD+ helps replenish these levels, empowering your body to perform at its best.

BP GHK-CU 50MG PEN

R 1800

GHK-Cu 50mg is a single-peptide injectable research compound containing 50 mg total GHK-Cu (Copper Tripeptide-1) per pen.

The prefilled pen allows precise dose selection of 1 mg, 2 mg, or 3 mg per injection, delivering controlled and consistent administration under research or practitioner guidance.

GHK-Cu is a naturally occurring copper-binding peptide widely studied in regenerative and cosmetic research.

GHK-Cu functions by binding copper ions and modulating multiple biological pathways involved in repair and regeneration. Research suggests it may:

Support gene expression related to tissue repair, collagen production, and skin renewal

Its ability to influence multiple cell types and signaling pathways makes it a key focus in regenerative research.

Use this product only as instructed by your research protocol or supervising practitioner.

Research protocols commonly involve daily or alternate-day administration, depending on study objectives

Like all research peptides, GHK-Cu may cause side effects, although not everyone will experience them.

BP CAGRISEMA 12MG PEN

R 2600

Semaglutide (GLP-1) – slows gastric emptying, regulates appetite, reduces cravings, and helps maintain stable blood sugar after meals.

Cagrilintide (Amylin analogue) – promotes satiety, regulates appetite, supports insulin control, and aids fat loss.

Together, these compounds mimic natural metabolic hormones and have been shown in studies to help participants lose up to 22.5% of their body weight.

The Cagrisema 12mg Pen features a built-in dosage selector for gradual adjustment:

This slow increase ensures optimal tolerance and effectiveness. Continue at a dosage that works well for you, as long as appetite control and weight loss progress are maintained.

With Body Pharm, you are assured of high purity peptides, precision dosing, and reliable quality. The Cagrisema 12mg Pen offers South Africans access to advanced weight management technology that works in harmony with a healthy lifestyle for lasting results.

BP RETATRUTIDE 64MG PEN

R 4600

Retatrutide is a medicine for weight loss and weight maintenance that contains the active substance Retatrutide. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. Retatrutide works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food. This will help you eat less food and reduce your body weight. Retatrutide should be used with a reduced-calorie meal plan and increased physical activity.

Unique Properties of Retatrutide:

● Triple Hormone Agonist: Retatrutide is a novel, triple hormone agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors. This unique mechanism offers superior appetite suppression and enhanced energy expenditure compared to traditional GLP-1 receptor agonists.

● Long-lasting Effects: Retatrutide has a longer half-life, which allows for more stable blood levels and more consistent weight loss results.

● Enhanced Metabolic Benefits: In addition to weight loss, Retatrutide improves metabolic parameters such as blood glucose levels, making it particularly effective for patients with type 2 diabetes or metabolic syndrome.

What Retatrutide is used for: Retatrutide is used for weight loss and weight maintenance in addition to diet and physical activity in adults who have:

● A BMI of 30 kg/m² or greater (with obesity) or

● A BMI of 27 kg/m² and less than 30 kg/m² (overweight) and weight-related health problems.

BMI (Body Mass Index) is a measure of your weight in relation to your height.

2. What you need to know before you use Retatrutide

Do not use Retatrutide if you:

● Are allergic to Retatrutide or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions: Talk to your doctor, pharmacist, or nurse before using Retatrutide or during treatment if you have:

● Effects on the digestive system: You may feel sick (nausea), be sick (vomiting), or have diarrhea. These side effects can cause dehydration (loss of fluids). It is important that you drink enough fluids to prevent dehydration. This is especially important if you have kidney problems. Talk to your doctor if you have any questions or concerns.

● Inflammation of the pancreas: If you have severe and ongoing pain in the stomach area, see a doctor straight away as this could be a sign of an inflamed pancreas (acute pancreatitis).

● Diabetes: Retatrutide must not be used as a substitute for insulin.

● Low blood sugar (hypoglycemia): Taking a sulfonylurea or insulin with Retatrutide might increase the risk of getting low blood sugar levels (hypoglycemia). Please see section 4 for the warning signs of low blood sugar levels. Your doctor may ask you to test your blood sugar levels. This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar.

● Diabetic eye disease (retinopathy): Fast improvements in blood sugar control may lead to a temporary worsening of diabetic eye disease. If you have diabetic eye disease and experience eye problems while taking this medicine, talk to your doctor.

Children and adolescents: This medicine is not recommended in children and adolescents under 18 years as there is no information on use in children below this age.

Other medicines and Retatrutide: Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.

Pregnancy and breastfeeding:

● This medicine should not be used during pregnancy, as it is not known if it may affect your unborn child. Therefore, it is recommended to use contraception while using this medicine. If you wish to become pregnant, you should stop using this medicine at least two months in advance. If you become or are pregnant, think you may be pregnant or are planning to have a baby when using this medicine, talk to your doctor straight away, as your treatment will need to be stopped.

● You should not use this medicine if you are breastfeeding, as it is unknown if it passes into breast milk.

Driving and using machines: Retatrutide is unlikely to affect your ability to drive and use machines. Some patients may feel dizzy when taking Retatrutide, mainly during the first 3 months of treatment (see section 4). If you feel dizzy, you should not drive or operate machines until you feel better. If you need any further information, talk to your doctor, pharmacist, or nurse.

For diabetics using this medicine in combination with a sulfonylurea or insulin, low blood sugar (hypoglycemia) may occur, which may reduce your ability to concentrate. Do not drive or use machines if you get any signs of low blood sugar. See section 2, ‘Warnings and precautions,’ for information on increased risk of low blood sugar and section 4 for the warning signs of low blood sugar. Talk to your doctor for further information.

Sodium content: This pen contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially ‘sodium-free’.

3. How to use Retatrutide

Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist, or nurse if you are not sure.

How much to use:

The recommended therapeutic long-term dosage is 8 mg weekly for weight loss purposes. Some users can tolerate higher dosages; please seek guidance from your practitioner if higher-than-recommended dosages are to be followed.

Your treatment will start at a low dose, which will be gradually increased over 16 weeks of treatment as follows:

When you first start using Retatrutide, the starting dose is 2 mg once weekly. Your practitioner will instruct you to gradually increase your dose every 4 weeks until you reach the recommended dose of 8 mg once weekly. Your practitioner may decide to keep you at a lower maintenance dosage. Once you reach the recommended dose of 8 mg, do not increase this dose further unless under the guidance of a practitioner. You will be told to follow the table below.

Dose escalation:

Week	Weekly Dose	Units to Inject
Week 1-4	2 mg	2 mg marker on dosage selector
Week 5-8	4 mg	4 mg marker on dosage selector
Week 9-12	8 mg	8 mg marker on dosage selector
From Week 13	12 mg	8 mg + 4 mg marker on dosage selector

*Body Pharm Retatrutide pen can be dosed to 8 mg by using the 8 mg marker on the dosage selector. Seek guidance from your practitioner as alternative dosing schedules are not covered in the scope of this leaflet.

Your practitioner will assess your treatment on a regular basis.

How Retatrutide is given:

Retatrutide is given as an injection under the skin (subcutaneous injection). Do not inject it into a vein or muscle. The best places to give the injection are the upper arms, stomach, or upper legs. Before you use the pen for the first time, ask your doctor or nurse how to use it. Detailed instructions for use are on the other side of this leaflet.

People with diabetes:

Tell your doctor if you have diabetes. Your doctor may adjust the dose of your diabetes medicines to prevent you from getting low blood sugar. Do not mix Retatrutide with other medicines that you inject (e.g., insulins). Do not use Retatrutide in combination with other medicines that contain GLP-1 receptor agonists.

When to use Retatrutide:

You should use this medicine once a week and, if possible, on the same day each week. You can give yourself the injection at any time of the day, regardless of meals. If necessary, you can change the day of your weekly injection of this medicine as long as it has been at least 3 days since your last injection. After selecting a new dosing day, continue with once-a-week dosing.

If you use more Retatrutide than you should:

Talk to your doctor straight away. You may get side effects such as feeling sick (nausea).

If you forget to use Retatrutide:

If you forgot to inject a dose and:

● It is 5 days or less since you should have used Retatrutide, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.

● It is more than 5 days since you should have used Retatrutide, skip the missed dose. Then inject your next dose as usual on your scheduled day.

● Do not take an extra dose or increase the dose to make up for the missed dose.

If you stop using Retatrutide: Do not stop using Retatrutide without talking to your doctor. If you stop using Retatrutide, your appetite may increase, and your weight may increase.

BP RETATRUTIDE 32MG PEN

R 3600

Talk to your doctor straight away. You may get side effects such as feeling sick (nausea).

– It is 5 days or less since you should have used Retatrutide, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.

– It is more than 5 days since you should have used Retatrutide, skip the missed dose. Then inject your next dose as usual on your scheduled day.

– Do not take an extra dose or increase the dose to make up for the missed dose.

If you stop using Retatrutide: Do not stop using Retatrutide without talking to your doctor. If you stop using Retatrutide, your appetite may increase, and your weight may increase.

BP TIRZEPATIDE 60MG PEN

R 3700

BP Tirzepatide 60 Pen (60mg Tirzepatide), this medication is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes

Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, recently developed and finally approved in May 2022 by the Food and Drug Administration for the treatment of T2DM as an adjunct to diet and exercise. In subjects with T2DM, dual GIP and GLP-1 receptor agonism with tirzepatide, compared to single GLP-1 receptor agonism with semaglutide, produced significantly more significant improvements in total insulin secretion rate and insulin sensitivity, reflecting a significant improvement compared to semaglutide.

Similar effects were also documented in another mechanistic trial comparing tirzepatide with dulaglutide, another GLP-1 receptor agonist, suggesting that dual receptor agonism might indeed be responsible for improving insulin sensitivity, especially since the observed effect was shown to be only partially attributable to weight loss. Furthermore, the effect of tirzepatide on delayed gastric emptying is comparable to that induced by single GLP-1 receptor agonism.

Blood Sugar Control: Tirzepatide mimics GLP-1 and GLI, regulating blood sugar levels. It prompts insulin release when blood sugar is high and reduces glucagon production, which raises blood sugar.

Weight Management: Tirzepatide promotes weight loss by increasing satiety, reducing food intake, and aiding in weight reduction.

Cardiovascular Benefits: Some studies suggest Tirzepatide may reduce the risk of heart-related complications in type 2 diabetes.

Dosage Instructions: Dosages of BP Tirzepatide 30 Pen vary based on the product and its use (diabetes or obesity).

For diabetes management, start with 2.5 mg once a week. Depending on the response and tolerance, increase to 5 mg or 7.5 mg once a week upwards of a maximum 15 mg per week.

For obesity treatment, the recommended dose is 5 mg once a week, administered on the same day weekly, at a time of your choosing.

Always adhere to your healthcare provider’s dosage instructions, tailored to your specific condition and response.

Gastrointestinal Issues: Nausea, vomiting, diarrhea, and abdominal pain, especially when starting, may improve over time.

Hypoglycemia: Tirzepatide has a lower risk of causing low blood sugar compared to some diabetes drugs, but it can still occur, particularly when used with other blood sugar-lowering medications.

Injection Site Reactions: Some individuals may experience redness, itching, or pain at the injection site.

Pancreatitis: Pancreas inflammation has been reported as a potential side effect although it is a rare side effect.

Kidney Function: Tirzepatide may affect kidney function, requiring monitoring in some cases.

Discuss potential side effects and concerns with your healthcare provider when considering Tirzepatide treatment.

Half-life: BP Tirzepatide boasts a relatively lengthy half-life of about one week, allowing for once-weekly dosing. This extended action duration contributes to its efficacy in managing blood sugar and promoting weight loss.

In summary, Tirzepatide effectively manages type 2 diabetes and aids in weight loss. It provides multiple advantages, including blood sugar control and weight management. However, like all medications, it may cause side effects, and proper dosing guidance should be followed under healthcare provider supervision.

BP TIRZEPATIDE 30MG PEN

R 2900

BP Tirzepatide 30 Pen (30mg Tirzepatide), this medication is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes